Kikuchi, Ryo Kawagoe, Tatsukata Hotta, Kazuki
Published in
BMC Ophthalmology
BackgroundImmune checkpoint inhibitors can cause various adverse effects. Recently it has been shown that Vogt–Koyanagi–Harada (VKH) disease-like uveitis can occur in patients treated with nivolumab.Case presentationA 69-year-old man developed bilateral panuveitis after nivolumab treatment for recurrent hypopharyngeal cancer. Slit lamp examination ...
Oliveira, Leandro Jonata Carvalho Gongora, Aline Bobato Lara Jardim, Denis Leonardo Fontes
Published in
Current Oncology Reports
Purpose of ReviewThe aim of this review is to highlight the clinical development of PD-1 and PD-L1 inhibitors in cancer therapy. We focus on detailing the registration trials that have led to FDA-approved indications of anti-PD-1 and anti-PD-L1 therapies and future strategies.Recent FindingsThe number of PD-1/PD-L1 inhibitors approved and in studie...
Zhao, Jing-Jing Wen, Xi-Zhi Ding, Ya Li, Dan-Dan Zhu, Bao-Yan Li, Jing-Jing Weng, De-Sheng Zhang, Xing Zhang, Xiao-Shi
Published in
Aging
Programmed cell death 1 (PD-1) checkpoint inhibitor therapy leads to immune-related adverse events (irAEs). We sought to evaluate whether the development of irAEs correlates with the treatment response in Chinese patients with advanced melanoma. In this study, we conducted a retrospective study of advanced melanoma patients who received PD-1 inhibi...
Schmid, Sebastian C. Koll, Florestan J. Rödel, Claus Maisch, Philipp Sauter, Andreas Beckert, Franziska Seitz, Anna Kübler, Hubert Flentje, Michael Chun, Felix
...
Published in
BMC Cancer
BackgroundPatients with locally advanced bladder cancer (cT3/4 cN0/N+ cM0) have a poor prognosis despite radical surgical therapy and perioperative chemotherapy. Preliminary data suggest that the combination of radiation and immunotherapy does not lead to excess toxicity and may have synergistic (abscopal) anti-tumor effects. We hypothesize that th...
Manohar, Sandhya Thongprayoon, Charat Cheungpasitporn, Wisit Markovic, Svetomir N. Herrmann, Sandra M.
Published in
Kidney International Reports
Introduction Kidney transplant (Ktx) recipients are excluded from clinical trials of immune checkpoint inhibitors. The aim of this systematic review was to assess the safety of immune checkpoint inhibitors among Ktx patients. Methods A literature search was conducted using MEDLINE, EMBASE, and Cochrane Database from inception through April 2019. We...
Hao, Zhaonian Guo, Dongsheng
Published in
BMC Cancer
BackgroundGlioma is one of the most common type of primary central nervous system tumors. EGFR mutation, a common alteration occurs in various tumors, is not brought to the forefront in understanding and treating glioma at present.MethodsIn the present study, we demonstrated an immune infiltration related pattern of EGFR mutation in lower-grade gli...
Abdallah, Nadine Nagasaka, Misako Chowdhury, Tahmida Raval, Kunil Hotaling, Jeffrey Sukari, Ammar
Published in
Oral oncology
Merkel cell carcinoma (MCC) is a rare but aggressive neuroendocrine skin malignancy. We report here a case of localized MCC achieving pathologic complete response upon treatment with avelumab in the neoadjuvant setting. Preclinical and clinical studies have revealed a close relationship between MCC and the immune system, thus supporting a role for ...
Hong, Ye Ding, Zhen-Yu
Published in
Frontiers in Pharmacology
Esophageal cancer (EC) is a lethal disease, and ranks 7th in incidence and 6th in mortality worldwide. Patients are treated with surgery and/or chemoradiotherapy for a curative intent, but for those with advanced diseases systemic chemotherapy and targeted therapy are the mainstay treatment with poor prognosis. For the patients with squamous cell c...
Kim, Jong Yeob Kronbichler, Andreas Eisenhut, Michael Hong, Sung Hwi van der Vliet, Hans J. Kang, Jeonghyun Shin, Jae Il Gamerith, Gabriele
Published in
Cancers
Tumor mutational burden (TMB) is a genomic biomarker that predicts favorable responses to immune checkpoint inhibitors (ICIs). Here, we set out to assess the predictive value of TMB on long-term survival outcomes in patients undergoing ICIs. We systematically searched PubMed, Embase, CENTRAL and clinicaltrials.gov from inception to 6 August 2019. W...
Fukihara, Jun Sakamoto, Koji Koyama, Junji Ito, Takayasu Iwano, Shingo Morise, Masahiro Ogawa, Masahiro Kondoh, Yasuhiro Kimura, Tomoki Hashimoto, Naozumi
...
Published in
Clinical lung cancer
Pneumonitis is one of the immune-related adverse events of programmed death 1 (PD-1) inhibitors that sometimes cause lethal outcomes. Although some recent reports have described PD-1 inhibitors as more effective in non-small-cell lung cancer (NSCLC) patients with immune-related adverse events than in those without, few data are available on the pro...
